Winfried MÃ¤rz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9668364/publications.pdf

Version: 2024-02-01

269 papers	31,486 citations	15001 68 h-index	6177 164 g-index
278 all docs	278 docs citations	278 times ranked	43105 citing authors

#	Article	IF	Citations
1	J-shaped association between circulating apoC-III and cardiovascular mortality. European Journal of Preventive Cardiology, 2022, 29, e68-e71.	0.8	2
2	Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial. Clinical Research in Cardiology, 2022, 111, 614-626.	1.5	8
3	GWAS meta-analysis followed by Mendelian randomization revealed potential control mechanisms for circulating Î±-Klotho levels. Human Molecular Genetics, 2022, 31, 792-802.	1.4	5
4	Meta-GWAS of PCSK9 levels detects two novel loci atAPOBandTM6SF2. Human Molecular Genetics, 2022, 31, 999-1011.	1.4	9
5	Evaluation of five widely used serologic assays for antibodies to SARS-CoV-2. Diagnostic Microbiology and Infectious Disease, 2022, 102, 115587.	0.8	6
6	Critical Appraisal of Large Vitamin D Randomized Controlled Trials. Nutrients, 2022, 14, 303.	1.7	59
7	Gender- and subgroup-specific sensitivity analysis of alcohol consumption and mortality in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Data in Brief, 2022, 41, 107873.	0.5	0
8	Short-Term Treatment with Alirocumab, Flow-Dependent Dilatation of the Brachial Artery and Use of Magnetic Resonance Diffusion Tensor Imaging to Evaluate Vascular Structure: An Exploratory Pilot Study. Biomedicines, 2022, 10, 152.	1.4	5
9	Genome-wide meta-analysis of phytosterols reveals five novel loci and a detrimental effect on coronary atherosclerosis. Nature Communications, 2022, 13, 143.	5.8	17
10	Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study. Biomedicines, 2022, 10, 193.	1.4	4
11	Identification of Specific Coronary Artery Disease Phenotypes Implicating Differential Pathophysiologies. Frontiers in Cardiovascular Medicine, 2022, 9, 778206.	1.1	3
12	Diagnostic Performance of Rapid Antigen Testing for SARS-CoV-2: The COVid-19 AntiGen (COVAG) study. Frontiers in Medicine, 2022, 9, 774550.	1.2	16
13	Genetically Determined Reproductive Aging and Coronary Heart Disease: A Bidirectional 2-sample Mendelian Randomization. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2952-e2961.	1.8	13
14	Effects of Vitamin D Supplementation on 24-Hour Blood Pressure in Patients with Low 25-Hydroxyvitamin D Levels: A Randomized Controlled Trial. Nutrients, 2022, 14, 1360.	1.7	9
15	High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study. European Journal of Preventive Cardiology, 2022, 29, 1731-1739.	0.8	3
16	Genome-wide studies reveal factors associated with circulating uromodulin and its relationships to complex diseases. JCI Insight, 2022, 7, .	2.3	12
17	The LDL Apolipoprotein B-to-LDL Cholesterol Ratio: Association with Cardiovascular Mortality and a Biomarker of Small, Dense LDLs. Biomedicines, 2022, 10, 1302.	1.4	5
18	Hypercalcemia in Pregnancy Due to CYP24A1 Mutations: Case Report and Review of the Literature. Nutrients, 2022, 14, 2518.	1.7	12

#	Article	IF	Citations
19	A scoring system for predicting individual treatment effects of statins in type 2 diabetes patients on haemodialysis. European Journal of Preventive Cardiology, 2021, 28, 838-851.	0.8	6
20	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. PLoS Medicine, 2021, 18, e1003513.	3.9	70
21	Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. Nature Communications, 2021, 12, 24.	5.8	87
22	Genome-wide association study of circulating interleukin 6 levels identifies novel loci. Human Molecular Genetics, 2021, 30, 393-409.	1.4	32
23	Associations of Serum Cortisol with Cardiovascular Risk and Mortality in Patients Referred to Coronary Angiography. Journal of the Endocrine Society, 2021, 5, bvab017.	0.1	6
24	Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. European Heart Journal, 2021, 42, 919-933.	1.0	113
25	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	1.0	63
26	Vitamin D and Cardiovascular Disease: An Updated Narrative Review. International Journal of Molecular Sciences, 2021, 22, 2896.	1.8	56
27	FGL1 as a modulator of plasma Dâ€dimer levels: Exomeâ€wide marker analysis of plasma tPA, PAIâ€1, and Dâ€dimer. Journal of Thrombosis and Haemostasis, 2021, 19, 2019-2028.	1.9	1
28	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis, 2021, 325, 99-109.	0.4	83
29	High Oxalate Concentrations Correlate with Increased Risk for Sudden Cardiac Death in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2021, 32, 2375-2385.	3.0	23
30	A hybrid data harmonization workflow using word embeddings for the interlinking of heterogeneous cross-domain clinical data structures. , 2021, , .		1
31	Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. Atherosclerosis, 2021, 330, 8-13.	0.4	10
32	Prior myocardial infarction, coronary artery disease extent, diabetes mellitus, and CERT2 score for risk stratification in stable coronary artery disease. European Journal of Preventive Cardiology, 2021, , .	0.8	5
33	Triglycerideâ€“Rich Lipoproteins, Apolipoproteins, and Atherosclerotic Cardiovascular Events Among Patients with Diabetes Mellitus and Endâ€“Stage Renal Disease on Hemodialysis. American Journal of Cardiology, 2021, 152, 63-68.	0.7	5
34	Alcohol consumption and mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Atherosclerosis, 2021, 335, 119-125.	0.4	7
35	Anemia of Chronic Disease in Patients With Cardiovascular Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 666638.	1.1	22
36	APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans. Nature, 2021, 597, 92-96.	13.7	38

#	Article	IF	Citations
37	Randomized Supplementation of Vitamin D versus Placebo on Markers of Systemic Inflammation in Hypertensive Patients. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3202-3209.	1.1	4
38	Cutaneous manifestations in familial hypercholesterolaemia. Atherosclerosis, 2021, 333, 116-123.	0.4	9
39	Combined Use of Serum Uromodulin and eGFR to Estimate Mortality Risk. Frontiers in Medicine, 2021, 8, 723546.	1.2	4
40	Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury. Journal of the American Society of Nephrology: JASN, 2021, 32, 3146-3160.	3.0	16
41	Lipid profiles of patients with manifest coronary versus peripheral atherosclerosis â€“ Is there a difference?. Journal of Internal Medicine, 2021, 290, 1249-1263.	2.7	4
42	The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541.	1.4	11
43	rs41291957 controls miRâ€143 and miRâ€145 expression and impacts coronary artery disease risk. EMBO Molecular Medicine, 2021, 13, e14060.	3.3	11
44	Interleukin-1Î± Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease. Circulation, 2021, 144, 893-908.	1.6	36
45	Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk. American Journal of Physiology - Renal Physiology, 2021, 321, G252-G261.	1.6	4
46	Immune Status and Mortality in Smokers, Ex-smokers, and Never-Smokers: The Ludwigshafen Risk and Cardiovascular Health Study. Nicotine and Tobacco Research, 2021, 23, 1191-1198.	1.4	5
47	Genetic Variation in Sodiumâ€glucose Cotransporter 2 and Heart Failure. Clinical Pharmacology and Therapeutics, 2021, 110, 149-158.	2.3	11
48	Individual uromodulin serum concentration is independent of glomerular filtration rate in healthy kidney donors. Clinical Chemistry and Laboratory Medicine, 2021, 59, 563-570.	1.4	9
49	FH ALERT: efficacy of a novel approach to identify patients with familial hypercholesterolemia. Scientific Reports, 2021, 11, 20421.	1.6	4
50	The power of genetic diversity in genome-wide association studies of lipids. Nature, 2021, 600, 675-679.	13.7	353
51	Epigenome-wide association study of serum urate reveals insights into urate co-regulation and the SLC2A9 locus. Nature Communications, 2021, 12, 7173.	5.8	8
52	Meta-analyses identify DNA methylation associated with kidney function and damage. Nature Communications, 2021, 12, 7174.	5.8	30
53	Area-based socioeconomic status and mortality: the Ludwigshafen Risk and Cardiovascular Health study. Clinical Research in Cardiology, 2020, 109, 103-114.	1.5	13
54	Subclinical inflammation, telomere shortening, homocysteine, vitamin B6, and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. European Journal of Nutrition, 2020, 59, 1399-1411.	1.8	38

#	Article	IF	Citations
55	Long- and short-term association of low-grade systemic inflammation with cardiovascular mortality in the LURIC study. Clinical Research in Cardiology, 2020, 109, 358-373.	1.5	10
56	Sunbeds and Melanoma Risk: Many Open Questions, Not Yet Time to Close the Debate. Anticancer Research, 2020, 40, 501-509.	0.5	5
57	Bile Acids in Patients with Uncontrolled Type 2 Diabetes Mellitus â€“ The Effect of Two Days of Oatmeal Treatment. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 624-630.	0.6	9
58	Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nature Immunology, 2020, 21, 30-41.	7.0	169
59	LDL receptor traffic: in the fast lane. European Heart Journal, 2020, 41, 1054-1056.	1.0	2
60	Influence of smoking and smoking cessation on biomarkers of endothelial function and their association with mortality. Atherosclerosis, 2020, 292, 52-59.	0.4	16
61	Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease. Atherosclerosis, 2020, 311, 84-90.	0.4	9
62	Association of Factor V Leiden With Subsequent Atherothrombotic Events. Circulation, 2020, 142, 546-555.	1.6	11
63	Cholesterol Efflux Capacity and Cardiovascular Disease: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Biomedicines, 2020, 8, 524.	1.4	15
64	NO Synthesis Markers Are Not Significantly Associated with Blood Pressure and Endothelial Dysfunction in Patients with Arterial Hypertension: A Cross-Sectional Study. Journal of Clinical Medicine, 2020, 9, 3895.	1.0	2
65	Associations of Thyroid Hormones and Resting Heart Rate in Patients Referred to Coronary Angiography. Hormone and Metabolic Research, 2020, 52, 850-855.	0.7	3
66	Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus. Scientific Reports, 2020, 10, 14158.	1.6	8
67	Effect of Galectin 3 on Aldosterone-Associated Risk of Cardiovascular Mortality in Patients Undergoing Coronary Angiography. American Journal of Cardiology, 2020, 127, 9-15.	0.7	2
68	Mendelian randomization analysis does not support causal associations of birth weight with hypertension risk and blood pressure in adulthood. European Journal of Epidemiology, 2020, 35, 685-697.	2.5	9
69	Composite Measures of Physical Fitness to Discriminate Between Healthy Aging and Heart Failure: The COmPLETE Study. Frontiers in Physiology, 2020, 11, 596240.	1.3	5
70	The association of high-normal international-normalized-ratio (INR) with mortality in patients referred for coronary angiography. PLoS ONE, 2019, 14, e0221112.	1.1	8
71	The Effect of Vitamin D Supplementation on its Metabolism and the Vitamin D Metabolite Ratio. Nutrients, 2019, 11, 2539.	1.7	16
72	Associations of autozygosity with a broad range of human phenotypes. Nature Communications, 2019, 10, 4957.	5.8	84

#	Article	IF	Citations
73	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. Atherosclerosis Supplements, 2019, 39, e1-e8.	1.2	31
74	Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis, 2019, 289, 206-213.	0.4	66
75	Association of Birth Weight With Type 2 Diabetes and Glycemic Traits. JAMA Network Open, 2019, 2, e1910915.	2.8	41
76	Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nature Genetics, 2019, 51, 1459-1474.	9.4	251
77	Association of soluble CD40L with short-term and long-term cardiovascular and all-cause mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Atherosclerosis, 2019, 291, 127-131.	0.4	12
78	Diagnostic Accuracy of the Aldosteroneâ€“toâ€“Active Renin Ratio for Detecting Primary Aldosteronism. Journal of the Endocrine Society, 2019, 3, 1748-1758.	0.1	6
79	Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation. JAMA Cardiology, 2019, 4, 144.	3.0	64
80	LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study. Atherosclerosis, 2019, 282, 37-44.	0.4	38
81	Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography. Scientific Reports, 2019, 9, 475.	1.6	8
82	Cardiovascular risk algorithms in primary care: Results from the DETECT study. Scientific Reports, 2019, 9, 1101.	1.6	15
83	Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort. Vascular Pharmacology, 2019, 120, 106566.	1.0	15
84	A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nature Genetics, 2019, 51, 957-972.	9.4	549
85	Mendelian randomization evaluation of causal effects of fibrinogen on incident coronary heart disease. PLoS ONE, 2019, 14, e0216222.	1.1	17
86	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	1.6	17
87	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	1.6	22
88	Vitamin D testing and treatment: a narrative review of current evidence. Endocrine Connections, 2019, 8, R27-R43.	0.8	172
89	Iron Metabolism, Hepcidin, and Mortality (the Ludwigshafen Risk and Cardiovascular Health Study). Clinical Chemistry, 2019, 65, 849-861.	1.5	23
90	Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study. Vascular Pharmacology, 2019, 116, 8-15.	1.0	20

#	Article	IF	Citations
91	Genome-wide association study suggests impact of chromosome 10 rs139401390 on kidney function in patients with coronary artery disease. Scientific Reports, 2019, 9, 2750.	1.6	6
92	Cardiovascular risk factors in patients with premature cardiovascular events attending the University of Dresden Lipid Clinic. Atherosclerosis Supplements, 2019, 40, 94-99.	1.2	8
93	Recurrent tendosynovitis as a rare manifestation of a lipid disorder. Journal of Clinical Lipidology, 2019, 13, 54-61.	0.6	3
94	Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels. Circulation, 2019, 139, 620-635.	1.6	102
95	Effect of Genetically Low 25-Hydroxyvitamin D on Mortality Risk: Mendelian Randomization Analysis in 3 Large European Cohorts. Nutrients, 2019, 11, 74.	1.7	30
96	A genome-wide association study identifies new loci for factor VII and implicates factor VII in ischemic stroke etiology. Blood, 2019, 133, 967-977.	0.6	34
97	The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction. Blood, 2019, 133, 356-365.	0.6	24
98	The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption. Journal of Lipid Research, 2019, 60, 161-167.	2.0	16
99	Dietary Intervention with Oatmeal in Patients with uncontrolled Type 2 Diabetes Mellitus â€“ A Crossover Study. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 623-629.	0.6	17
100	Renal function, N-terminal Pro-B-Type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction. Peptides, 2019, 111, 112-117.	1.2	8
101	Effects of vitamin D supplementation on FGF23: a randomized-controlled trial. European Journal of Nutrition, 2019, 58, 697-703.	1.8	19
102	The effect of vitamin D supplementation on plasma non-oxidised PTH in a randomised clinical trial. Endocrine Connections, 2019, 8, 518-527.	0.8	8
103	Telomere length, vitamin B12 and mortality in persons undergoing coronary angiography: the Ludwigshafen risk and cardiovascular health study. Aging, 2019, 11, 7083-7097.	1.4	14
104	Are soluble ST2 levels influenced by vitamin D and/or the seasons?. Endocrine Connections, 2019, 8, 691-700.	0.8	1
105	Prospective cohort studies of beta-trace protein and mortality in haemodialysis patients and patients undergoing coronary angiography. Nephrology Dialysis Transplantation, 2018, 33, 1984-1991.	0.4	3
106	Telomere biology and age-related diseases. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1210-1222.	1.4	125
107	Saturated fatty acids and mortality in patients referred for coronary angiographyâ€"The Ludwigshafen Risk and Cardiovascular Health study. Journal of Clinical Lipidology, 2018, 12, 455-463.e3.	0.6	30
108	Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels. Nature Communications, 2018, 9, 260.	5.8	295

#	Article	IF	Citations
109	Prognostic Value of High-Sensitivity Versus Conventional Cardiac Troponin T Assays Among Patients With Type 2 Diabetes Mellitus Undergoing Maintenance Hemodialysis. American Journal of Kidney Diseases, 2018, 71, 822-830.	2.1	17
110	Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data. Hormone and Metabolic Research, 2018, 50, 375-382.	0.7	10
111	Adverse effects of statin therapy: perception vs. the evidence â€“ focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	1.0	262
112	Associations of fats and carbohydrates with cardiovascular disease and mortalityâ€”PURE and simple?. Lancet, The, 2018, 391, 1680-1681.	6.3	0
113	Vitamin D supplementation and lipoprotein metabolism: A randomized controlled trial. Journal of Clinical Lipidology, 2018, 12, 588-596.e4.	0.6	36
114	Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis, 2018, 268, 99-107.	0.4	53
115	The UGT1A1*28 gene variant predicts long-term mortality in patients undergoing coronary angiography. Clinical Chemistry and Laboratory Medicine, 2018, 56, 560-564.	1.4	5
116	Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry. Atherosclerosis, 2018, 277, 314-322.	0.4	27
117	The Role of Vitamin D in Fertility and during Pregnancy and Lactation: A Review of Clinical Data. International Journal of Environmental Research and Public Health, 2018, 15, 2241.	1.2	101
118	Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. American Journal of Human Genetics, 2018, 103, 691-706.	2.6	326
119	Rationale and Plan for Vitamin D Food Fortification: A Review and Guidance Paper. Frontiers in Endocrinology, 2018, 9, 373.	1.5	249
120	A new non-invasive diagnostic tool in coronary artery disease: artificial intelligence as an essential element of predictive, preventive, and personalized medicine. EPMA Journal, 2018, 9, 235-247.	3.3	23
121	Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233.	9.4	552
122	Case reportâ€”Rapid regression of xanthomas under lipoprotein apheresis in a boy with homozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 868-871.	0.6	4
123	Telomere length and mortality in the Ludwigshafen Risk and Cardiovascular Health study. PLoS ONE, 2018, 13, e0198373.	1.1	31
124	Vitamin D: Current Guidelines and Future Outlook. Anticancer Research, 2018, 38, 1145-1151.	0.5	37
125	Solarium Use and Risk for Malignant Melanoma: Meta-analysis and Evidence-based Medicine Systematic Review. Anticancer Research, 2018, 38, 1187-1199.	0.5	19
126	Serum Uromodulin and Mortality Risk in Patients Undergoing Coronary Angiography. Journal of the American Society of Nephrology: JASN, 2017, 28, 2201-2210.	3.0	79

#	Article	IF	Citations
127	Chronic kidney disease in primary care in Germany. Zeitschrift Fur Gesundheitswissenschaften, 2017, 25, 223-230.	0.8	10
128	Beta-trace Protein as a new non-invasive immunological Marker for Quinolinic Acid-induced impaired Blood-Brain Barrier Integrity. Scientific Reports, 2017, 7, 43642.	1.6	18
129	Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nature Genetics, 2017, 49, 946-952.	9.4	279
130	Copeptin Associates with Cause-Specific Mortality in Patients with Impaired Renal Function: Results from the LURIC and the 4D Study. Clinical Chemistry, 2017, 63, 997-1007.	1.5	11
131	Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study. European Journal of Preventive Cardiology, 2017, 24, 1095-1101.	0.8	7
132	Vitamin-D concentrations, cardiovascular risk and events - a review of epidemiological evidence. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 259-272.	2.6	59
133	The biomarker and causal roles of homoarginine in the development of cardiometabolic diseases: an observational and Mendelian randomization analysis. Scientific Reports, 2017, 7, 1130.	1.6	18
134	Omega-6 fatty acids: Opposing associations with riskâ€"The Ludwigshafen Risk and Cardiovascular Health Study. Journal of Clinical Lipidology, 2017, 11, 1082-1090.e14.	0.6	29
135	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	5.5	84
136	Myeloperoxidase, asymmetric dimethyl-arginine and the renin-angiotensin-aldosterone-system in cardiovascular risk patients: Cross-sectional findings from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clinical Biochemistry, 2017, 50, 739-745.	0.8	11
137	Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease. European Heart Journal, 2017, 38, 1597-1607.	1.0	77
138	HDL cholesterol: reappraisal of its clinical relevance. Clinical Research in Cardiology, 2017, 106, 663-675.	1.5	186
139	Genetic Variants Associated with Circulating Parathyroid Hormone. Journal of the American Society of Nephrology: JASN, 2017, 28, 1553-1565.	3.0	52
140	High-Density Lipoprotein Subclasses, Coronary Artery Disease, and Cardiovascular Mortality. Clinical Chemistry, 2017, 63, 1886-1896.	1.5	28
141	Plasma parathyroid hormone and cardiovascular disease in treatmentâ€naive patients with primary hyperparathyroidism: The <scp>EPATH</scp> trial. Journal of Clinical Hypertension, 2017, 19, 1173-1180.	1.0	14
142	Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study. Atherosclerosis, 2017, 266, 24-30.	0.4	26
143	Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism â€“ The randomized, placebo-controlled EPATH trial. Bone, 2017, 105, 212-217.	1.4	8
144	Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium. Scientific Reports, 2017, 7, 11303.	1.6	15

#	Article	IF	Citations
145	Association analyses based on false discovery rate implicate new loci for coronary artery disease. Nature Genetics, 2017, 49, 1385-1391.	9.4	571
146	CaRe high â€“ Cascade screening and registry for high cholesterol in Germany. Atherosclerosis Supplements, 2017, 30, 72-76.	1.2	12
147	Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. International Journal of Clinical Practice, 2017, 71, e12979.	0.8	11
148	Biomarker-Based Risk Model to PredictÂCardiovascular Mortality in PatientsÂWithÂStableÂCoronaryÂDisease. Journal of the American College of Cardiology, 2017, 70, 813-826.	1.2	95
149	Refining Long-Term Prediction of Cardiovascular Risk in Diabetes â€“ The VILDIA Score. Scientific Reports, 2017, 7, 4700.	1.6	11
150	ST2 predicts survival in patients undergoing transcatheter aortic valve implantation. International Journal of Cardiology, 2017, 244, 87-92.	0.8	17
151	Propeptide big-endothelin, N-terminal-pro brain natriuretic peptide and mortality. The Ludwigshafen risk and cardiovascular health (LURIC) study. Biomarkers, 2017, 22, 315-320.	0.9	3
152	Individual omega-9 monounsaturated fatty acids and mortalityâ€”The Ludwigshafen Risk and Cardiovascular Health Study. Journal of Clinical Lipidology, 2017, 11, 126-135.e5.	0.6	61
153	Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. Free Radical Research, 2017, 51, 14-23.	1.5	9
154	Vitamin D and chronic diseases: the current state of the art. Archives of Toxicology, 2017, 91, 97-107.	1.9	108
155	Leucocyte immunoglobulin-like receptor subfamily-B5 (LILRB5) genetic variation and statin-associated muscle symptoms: another piece in a puzzling puzzle. European Heart Journal, 2017, 38, 3576-3578.	1.0	9
156	Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial. Nutrients, 2017, 9, 432.	1.7	39
157	Genome-Wide Association Analysis for Severity of Coronary Artery Disease Using the Gensini Scoring System. Frontiers in Cardiovascular Medicine, 2017, 4, 57.	1.1	14
158	Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial. Nutrients, 2017, 9, 623.	1.7	33
159	Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial. PLoS ONE, 2017, 12, e0173799.	1.1	10
160	Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. PLoS Medicine, 2017, 14, e1002383.	3.9	341
161	Vitamin D and mortality: Individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a European consortium. PLoS ONE, 2017, 12, e0170791.	1.1	219
162	Genome-wide physical activity interactions in adiposity â€• A meta-analysis of 200,452 adults. PLoS Genetics, 2017, 13, e1006528.	1.5	158

#	Article	IF	Citations
163	Comparison of HapMap and 1000 Genomes Reference Panels in a Large-Scale Genome-Wide Association Study. PLoS ONE, 2017, 12, e0167742.	1.1	29
164	Neutrophil gelatinase-associated lipocalin levels are U-shaped in the Ludwigshafen Risk and Cardiovascular Health (LURIC) studyâ€"Impact for mortality. PLoS ONE, 2017, 12, e0171574.	1.1	14
165	Vitamin D Supplementation and Hemoglobin Levels in Hypertensive Patients: A Randomized Controlled Trial. International Journal of Endocrinology, 2016, 2016, 1-7.	0.6	19
166	PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR. PLoS ONE, 2016, 11, e0146920.	1.1	35
167	Omega-3 fatty acids and mortality in patients referred for coronary angiography. The Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis, 2016, 252, 175-181.	0.4	75
168	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90
169	Associations of functional alanine-glyoxylate aminotransferase 2 gene variants with atrial fibrillation and ischemic stroke. Scientific Reports, 2016, 6, 23207.	1.6	20
170	Cholesterol Efflux Capacity. Journal of the American College of Cardiology, 2016, 67, 2488-2491.	1.2	5
171	Vitamin D and cardiovascular disease prevention. Nature Reviews Cardiology, 2016, 13, 404-417.	6.1	250
172	Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. European Heart Journal, 2016, 37, 1967-1976.	1.0	433
173	Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia. Atherosclerosis, 2016, 253, 88-93.	0.4	35
174	Research update for articles published in <scp>EJCI</scp> in 2014. European Journal of Clinical Investigation, 2016, 46, 880-894.	1.7	2
175	Data on gender and subgroup specific analyses of omega-3 fatty acids in the Ludwigshafen Risk and Cardiovascular Health Study. Data in Brief, 2016, 8, 1311-1321.	0.5	7
176	Discovery and refinement of genetic loci associated with cardiometabolic risk using dense imputation maps. Nature Genetics, 2016, 48, 1303-1312.	9.4	66
177	Adiponectin and Mortality in Smokers and Non-Smokers of the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Advances in Experimental Medicine and Biology, 2016, 934, 1-8.	0.8	4
178	Systematic review of published Phase 3 data on antiâ€PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. British Journal of Clinical Pharmacology, 2016, 82, 1412-1443.	1.1	36
179	Effects of Vitamin D Supplementation on Plasma Aldosterone and Reninâ€"A Randomized Placeboâ€Controlled Trial. Journal of Clinical Hypertension, 2016, 18, 608-613.	1.0	34
180	Genome-Wide Association Study of the Modified Stumvoll Insulin Sensitivity Index Identifies BCL2 and FAM19A2 as Novel Insulin Sensitivity Loci. Diabetes, 2016, 65, 3200-3211.	0.3	67

#	Article	IF	Citations
181	LDL-Cholesterol: Standards of Treatment 2016: A German Perspective. American Journal of Cardiovascular Drugs, 2016, 16, 323-336.	1.0	18
182	No Association of Coronary Artery Disease with X-Chromosomal Variants in Comprehensive International Meta-Analysis. Scientific Reports, 2016, 6, 35278.	1.6	25
183	Fast and Accurate Construction of Confidence Intervals for Heritability. American Journal of Human Genetics, 2016, 98, 1181-1192.	2.6	31
184	The Renin-Angiotensin-Aldosterone System in Smokers and Non-Smokers of the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Advances in Experimental Medicine and Biology, 2016, 935, 75-82.	0.8	7
185	Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis. International Journal of Epidemiology, 2016, 45, 1927-1937.	0.9	94
186	Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2Âdiabetes mellitus on hemodialysis. Kidney International, 2016, 89, 1380-1387.	2.6	27
187	Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. Nature Communications, 2016, 7, 10494.	5.8	153
188	Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study. Nephrology Dialysis Transplantation, 2016, 31, 1901-1908.	0.4	31
189	A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. Human Molecular Genetics, 2016, 25, 358-370.	1.4	73
190	Trans-fatty acids and mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health Study. European Heart Journal, 2016, 37, 1072-1078.	1.0	73
191	Vitamin D and Mortality. Anticancer Research, 2016, 36, 1379-87.	0.5	28
192	Human Pigmentation, Cutaneous Vitamin D Synthesis and Evolution: Variants of Genes (SNPs) Involved in Skin Pigmentation Are Associated with 25(OH)D Serum Concentration. Anticancer Research, 2016, 36, 1429-37.	0.5	18
193	Lipoprotein(a): when to measure, how to treat?. Laboratoriums Medizin, 2015, 39, .	0.1	1
194	Lipoprotein(a): wann messen, wie behandeln?. Laboratoriums Medizin, 2015, 39, 71-80.	0.1	0
195	Statin intolerance. Current Opinion in Lipidology, 2015, 26, 492-501.	1.2	32
196	Differential Network Analysis with Multiply Imputed Lipidomic Data. PLoS ONE, 2015, 10, e0121449.	1.1	3
197	Treatment Options for Statin-Associated Muscle Symptoms. Deutsches Ärzteblatt International, 2015, 112, 748-55.	0.6	65
198	Statin-associated muscle symptoms: impact on statin therapyâ€"European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 2015, 36, 1012-1022.	1.0	1,024

#	Article	IF	Citations
199	Intestinal Cholesterol Absorption, Treatment With Atorvastatin, and Cardiovascular Risk in Hemodialysis Patients. Journal of the American College of Cardiology, 2015, 65, 2291-2298.	1.2	34
200	Quantification of HDL Proteins, Cardiac Events, and Mortality in Patients with Type 2 Diabetes on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 224-231.	2.2	54
201	Severe hypertriglyceridemia in a patient heterozygous for a lipoprotein lipase gene allele with two novel missense variants. European Journal of Human Genetics, 2015, 23, 1259-1261.	1.4	9
202	New genetic loci link adipose and insulin biology to body fat distribution. Nature, 2015, 518, 187-196.	13.7	1,328
203	Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015, 518, 197-206.	13.7	3,823
204	Von Willebrand Factor Improves Risk Prediction in Addition to N-Terminal Proâ€“B-type Natriuretic Peptide in Patients Referred to Coronary Angiography and Signs and Symptoms of Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2015, 8, 25-32.	1.6	25
205	Galectin-3, Renal Function, and Clinical Outcomes. Journal of the American Society of Nephrology: JASN, 2015, 26, 2213-2221.	3.0	111
206	Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk. International Journal of Cardiology, 2015, 184, 710-716.	0.8	24
207	Cotinine as a marker for risk prediction in the Ludwigshafen Risk and Cardiovascular Health Study. Respiratory Physiology and Neurobiology, 2015, 209, 17-22.	0.7	4
208	Uric Acid and Cardiovascular Events. Journal of the American Society of Nephrology: JASN, 2015, 26, 2831-2838.	3.0	216
209	Predicting sudden cardiac death using common genetic risk variants for coronary artery disease. European Heart Journal, 2015, 36, 1669-1675.	1.0	26
210	Effects of Vitamin D on Blood Pressure and Cardiovascular Risk Factors. Hypertension, 2015, 65, 1195-1201.	1.3	152
211	Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nature Genetics, 2015, 47, 1282-1293.	9.4	294
212	Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2015, 8, 1059-1067.	1.6	42
213	Soluble klotho and mortality: The Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis, 2015, 242, 483-489.	0.4	38
214	A comprehensive 1000 Genomesâ€“based genome-wide association meta-analysis of coronary artery disease. Nature Genetics, 2015, 47, 1121-1130.	9.4	2,054
215	Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. European Heart Journal, 2015, 36, ehv352.	1.0	116
216	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature, 2015, 518, 102-106.	13.7	581

#	Article	IF	Citations
217	HDL Cholesterol, Apolipoproteins, and Cardiovascular Risk in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2015, 26, 484-492.	3.0	37
218	Low-density lipoprotein particle diameter and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. European Heart Journal, 2015, 36, 31-38.	1.0	34
219	Vitamin D in preventive medicine. Anticancer Research, 2015, 35, 1161-70.	0.5	11
220	Single Nucleotide Variants in the Protein C Pathway and Mortality in Dialysis Patients. PLoS ONE, 2014, 9, e97251.	1.1	6
221	Integrative Genomics Reveals Novel Molecular Pathways and Gene Networks for Coronary Artery Disease. PLoS Genetics, 2014, 10, e1004502.	1.5	192
222	Immune Activation and Inflammation in Patients with Cardiovascular Disease Are Associated with Higher Phenylalanine to Tyrosine Ratios: The Ludwigshafen Risk and Cardiovascular Health Study. Journal of Amino Acids, 2014, 2014, 1-6.	5.8	72
223	EPIQâ€"efficient detection of SNPâ€“SNP epistatic interactions for quantitative traits. Bioinformatics, 2014, 30, i19-i25.	1.8	11
224	Associations of Methylarginines and Homoarginine With Diastolic Dysfunction and Cardiovascular Risk Factors in Patients With Preserved Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 2014, 20, 923-930.	0.7	35
225	The Arachidonic Acid Metabolome Serves as a Conserved Regulator of Cholesterol Metabolism. Cell Metabolism, 2014, 20, 787-798.	7.2	92
226	Familial Hypercholesterolemia. Deutsches Ärzteblatt International, 2014, 111, 523-9.	0.6	62
227	Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiographyâ€"The LURIC study. International Journal of Cardiology, 2014, 174, 96-105.	0.8	32
228	Gene-centric Meta-analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood-Pressure-Related Loci. American Journal of Human Genetics, 2014, 94, 349-360.	2.6	158
229	Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease. , 2014, 24, 65-71.		7
230	Novel Genetic Markers Associate With Atrial Fibrillation Risk in Europeans and Japanese. Journal of the American College of Cardiology, 2014, 63, 1200-1210.	1.2	127
231	Hemoglobin, iron metabolism and angiographic coronary artery disease (The Ludwigshafen Risk and) Tj ETQq1 1 0.784314 rgBT /Over	0.4	39
232	Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients. Atherosclerosis, 2014, 236, 263-269.	0.4	12
233	HDL Cholesterol Is Not Associated with Lower Mortality in Patients with Kidney Dysfunction. Journal of the American Society of Nephrology: JASN, 2014, 25, 1073-1082.	3.0	86
234	Fibroblast growth factor 23 (FGF23) and mortality: The Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis, 2014, 237, 53-59.	0.4	79

#	Article	IF	Citations
235	Defining the role of common variation in the genomic and biological architecture of adult human height. Nature Genetics, 2014, 46, 1173-1186.	9.4	1,818
236	Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis. Drugs, 2014, 74, 513-520.	4.9	0
237	Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. Lancet Diabetes and Endocrinology,the, 2014, 2, 719-729.	5.5	319
238	Association of the novel single-nucleotide polymorphism which increases oxidized low-density lipoprotein levels with cerebrovascular disease events. Atherosclerosis, 2014, 234, 214-217.	0.4	12
239	Discovery and refinement of loci associated with lipid levels. Nature Genetics, 2013, 45, 1274-1283.	9.4	2,641
240	Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature, 2013, 504, 432-436.	13.7	230
241	High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. European Heart Journal, 2013, 34, 3563-3571.	1.0	110
242	Causal Relationship between Obesity and Vitamin D Status: Bi-Directional Mendelian Randomization Analysis of Multiple Cohorts. PLoS Medicine, 2013, 10, e1001383.	3.9	753
243	The importance of assays in vitamin D status classification: a comparison of four automated 25-hydroxyvitamin D immunoassays. Laboratoriums Medizin, 2013, 37, 261-268.	0.1	7
244	Vitamin D und kardiovaskulÃre Erkrankungen: Standortbestimmung 2012/Vitamin D and cardiovascular diseases: where do we stand in 2012?. Laboratoriums Medizin, 2012, 36, .	0.1	2
245	Research update for articles published in EJCI in 2010. European Journal of Clinical Investigation, 2012, 42, 1149-1164.	1.7	1
246	Changes in the Prevalence, Treatment and Control of Hypertension in Germany? A Clinical-Epidemiological Study of 50.000 Primary Care Patients. PLoS ONE, 2012, 7, e52229.	1.1	32
247	Symmetrical and Asymmetrical Dimethylarginine as Predictors for Mortality in Patients Referred for Coronary Angiography: The Ludwigshafen Risk and Cardiovascular Health Study. Clinical Chemistry, 2011, 57, 112-121.	1.5	98
248	Association of Plasma Aldosterone With Cardiovascular Mortality in Patients With Low Estimated GFR: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. American Journal of Kidney Diseases, 2011, 57, 403-414.	2.1	42
249	Absoluter Aldosteronexzess, Bluthochdruck und koronare Herzerkrankung / Arterial hypertension and cardiovascular disease â€“ absolute aldosterone excess is the tip of the iceberg. Laboratoriums Medizin, 2011, 35, 147-151.	0.1	0
250	Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1316-1325.	2.2	116
251	Homoarginine, Cardiovascular Risk, and Mortality. Circulation, 2010, 122, 967-975.	1.6	164
252	Cholesteryl Ester Transfer Protein and Mortality in Patients Undergoing Coronary Angiography. Circulation, 2010, 121, 366-374.	1.6	97

#	Article	IF	Citations
253	Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. European Heart Journal, 2010, 31, 1237-1247.	1.0	141
254	Vitamin D deficiency: a global health problem 1. Laboratoriums Medizin, 2008, 32, -.	0.1	0
255	Asymmetrical Dimethylarginine Independently Predicts Total and Cardiovascular Mortality in Individuals with Angiographic Coronary Artery Disease (The Ludwigshafen Risk and Cardiovascular) Tj ETQq1 1 0.784314 rgBT /Overlock	1.5	209
256	Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clinica Chimica Acta, 2007, 384, 141-148.	0.5	76
257	Low density lipoprotein cholesterol, statins and cardiovascular events: a metaâ€“analysis. Clinical Research in Cardiology, 2006, 95, 393-404.	1.5	57
258	Adiponektin, ein Adipokin mit groÃŸem Potenzial fÃ¼r Diagnostik und Therapie des metabolischen Syndroms und assoziierter kardiovaskulÃrer Erkrankungen / Adiponectin, an adipokine as a promising target for diagnosis and therapy of the metabolic syndrome and associated cardiovascular diseases. Das Medizinische Laboratorium, 2006, 30, 187-191.	0.0	0
259	Smoking, apolipoprotein E genotype, and early onset of coronary heart disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 268-270.	3.1	0
260	Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. New England Journal of Medicine, 2005, 353, 238-248.	13.9	2,363
261	Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics. Kidney and Blood Pressure Research, 2004, 27, 259-266.	0.9	131
262	G(â^'30)A Polymorphism in the Pancreatic Promoter of the Glucokinase Gene Associated With Angiographic Coronary Artery Disease and Type 2 Diabetes Mellitus. Circulation, 2004, 109, 2844-2849.	1.6	48
263	Inflammatorische Biomarker und Atherosklerose/Inflammatory biomarkers and atherosclerosis. Laboratoriums Medizin, 2004, 28, 346-353.	0.1	0
264	Low-Density Lipoprotein Triglycerides Associated With Low-Grade Systemic Inflammation, Adhesion Molecules, and Angiographic Coronary Artery Disease. Circulation, 2004, 110, 3068-3074.	1.6	133
265	The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5	1.0	78
266	Rationale and design of the LURIC study - a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics, 2001, 2, S1-S73.	0.6	321
267	Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Kidney International, 1999, 56, S222-S226.	2.6	86
268	Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/Î±2-macroglobulin receptor. FEBS Letters, 1993, 325, 271-275.	1.3	74
269	Polyvascular disease, pulse pressure and mortality. Vasa - European Journal of Vascular Medicine, 0, , .	0.6	1